To this end, and in agreement with earlier reports [13], [14], we first demonstrated that CD133+/EpCAM+ tumor cells are tumor-initiating CSCs in the studied patient colorectal tumor by conducting the tumorigenesis assay in immunodeficient mice (Fig. 2A). This evidence concerns the gene PROM1 and colorectal neoplasm.